| Literature DB >> 33116441 |
Jamuna Rani Appalasamy1,2, Kia Fatt Quek1, Anuar Zaini Md Zain1, Joyce Pauline Joseph3, Siva Seeta Ramaiah4, Kyi Kyi Tha1.
Abstract
INTRODUCTION: Self-efficacy is positively associated with medication understanding and use self-efficacy (MUSE) among post-stroke patients. It is also closely related to knowledge, belief, and perception, which vary among people from different socioeconomic backgrounds and cultures. As interventions using video and peer stories have emerged to be successful on behavior modification, this study aimed to explore the effectiveness of video narratives incorporated with Health Belief constructs on MUSE and its associated factors among patients with stroke at a local setting.Entities:
Keywords: Health Belief Model; medication understanding and use self-efficacy; patient education; randomized controlled trial; stroke; video narratives
Year: 2020 PMID: 33116441 PMCID: PMC7585263 DOI: 10.2147/PPA.S253918
Source DB: PubMed Journal: Patient Prefer Adherence ISSN: 1177-889X Impact factor: 2.711
Figure 1Flowchart of the trial. **Patients available for analysis. Nevertheless, intention-to-treat analysis (ITT) was undertaken. Therefore, finalized number of patients for analysis were 108 of them from each group.
Socio-Demographic Data of Patients at Baseline (n=216)
| Characteristics | Control | Intervention | |
|---|---|---|---|
| Gender | Male | 73 (67.6) | 69 (63.9) |
| Female | 35 (32.4) | 39 (36.1) | |
| Age (years) | ≥ 60 | 52 (48.1) | 45 (41.7) |
| 40 - 59 | 46 (42.6) | 51 (47.2) | |
| ≤ 39 | 10 (9.3) | 12 (11.1) | |
| 57 ± 12.2 | 54 ± 12.4 | ||
| Ethnicity | Malay | 63 (58.3) | 77 (71.3) |
| Chinese | 11 (10.2) | 14 (13.0) | |
| Indian | 31 (28.7) | 16 (14.8) | |
| Others | 3 (2.8) | 1 (0.9) | |
| Education completion | Primary | 22 (20.4) | 20 (18.5) |
| Secondary | 62 (57.4) | 59 (54.6) | |
| Tertiary | 24 (22.2) | 29 (26.9) | |
| Health literacy | Adequate | 85 (78.7) | 84 (77.8) |
| Limited | 23 (21.3) | 24 (22.2) | |
| Employment | Employed | 44 (40.7) | 47 (43.5) |
| Unemployed | 64 (59.3) | 61 (56.5) | |
| Types of stroke | Ischemic | 91 (84.2) | 93 (86.1) |
| Hemorrhagic | 3 (2.8) | 6 (5.6) | |
| TIA | 14 (13.0) | 9 (8.3) | |
| Stroke comorbidities | Hypertension | 30 (27.8) | 29 (26.9) |
| Hypertension and other risks* | 69 (63.9) | 73 (67.5) | |
| Diabetes and other risks* | 9 (8.3) | 6 (5.6) | |
| Prescribed medication (types) | ≤ 2 | 15 (13.9) | 18 (16.7) |
| ≥ 3 | 93 (86.1) | 90 (83.3) | |
| Systolic pressure (mmHg) | 141 (20.7)c | 140 (21.3)c | |
| 23 (5.3)c | 23 (5.4)c | ||
| 7 (3.5)c | 6 (3.6)c | ||
| 51 (11.1)c | 50 (12.1)c |
Notes: aAssessed based on The Newest Vital Sign, bStroke code ICD-10, cMean ± SD. *Inclusive of modifiable stroke risk factors other than hypertension, eg, diabetes, heart diseases, hyperlipidemia, current smoking/alcohol.
Abbreviations: BIPQ, Brief Illness and Perception Questionnaire; BMQ, Belief About Medicine Questionnaire; BP, blood pressure; MUSE, medication understanding and use self-efficacy; SKT, Stroke Knowledge Test; TIA, transient ischemic attack.
Groups’ Comparison at Various Timelines
| Timeline (Month) | Within Group | Between Groups | (Timeline*Group) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| T0 (SD) | T2 (SD) | T4 (SD) | F | p | ƞ2 | F | p | ƞ2 | F | p | ƞ2 | ||
| MUSEa | I | 22.97 (5.17) | 27.27 (3.25) | 27.81 (2.52) | 97.00 | <0.001** | 0.475 | 12.41 | 0.001** | 0.055 | 42.99 | <0.001** | 0.167 |
| C | 23.71 (5.44) | 24.62 (4.03) | 24.42 (4.02) | 5.61 | 0.010* | 0.050 | |||||||
| MUSEb | I | 25.00 (5.85) | 27.82 (2.96) | 28.38 (3.23) | 42.05 | <0.001** | 0.282 | 5.10 | 0.025* | 0.023 | 6.91 | 0.005* | 0.205 |
| C | 24.75 (5.80) | 26.29 (4.97) | 26.28 (4.88) | 14.76 | <0.001** | 0.121 | |||||||
| MUSEc | I | 25.61 (5.71) | 28.88 (3.43) | 28.19 (3.18) | 49.11 | <0.001** | 0.315 | 7.25 | 0.008* | 0.033 | 12.22 | <0.001** | 0.195 |
| C | 25.29 (5.61) | 26.39 (5.02) | 26.25 (4.73) | 8.22 | 0.003* | 0.071 | |||||||
| Sys/BP | I | 141.68 (20.21) | 134.26 (14.96) | 135.71 (13.88) | 35.67 | <0.001** | 0.250 | 0.35 | 0.552 | 0.002 | 8.537 | 0.001** | 0.038 |
| C | 139.89 (21.31) | 137.59 (15.78) | 138.11 (15.73) | 3.37 | 0.055 | 0.031 | |||||||
| SKT | I | 7.47 (3.40) | 9.34 (3.09) | 9.79 (3.11) | 137.64 | <0.001** | 0.563 | 11.54 | 0.001** | 0.051 | 32.39 | <0.001** | 0.131 |
| C | 6.83 (3.59) | 7.49 (3.36) | 7.81 (3.28) | 42.93 | <0.001** | 0.286 | |||||||
| BIPQ | I | 52.08 (10.06) | 47.44 (9.29) | 47.79 (8.81) | 53.84 | <0.001** | 0.335 | 1.73 | 0.190 | 0.008 | 34.16 | <0.001** | 0.104 |
| C | 50.76 (12.12) | 51.08 (11.89) | 51.15 (12.77) | 0.42 | 0.594 | 0.004 | |||||||
| BMQ | I | 51.46 (6.22) | 48.22 (6.31) | 47.57 (6.15) | 51.39 | <0.001** | 0.324 | 15.93 | <0.001** | 0.069 | 71.76 | <0.001** | 0.251 |
| C | 50.91 (6.22) | 52.76 (7.11) | 53.74 (8.00) | 23.82 | <0.001** | 0.182 | |||||||
| BP/Mon | I | 2.41 (0.94) | 2.76 (0.98) | 2.87 (1.04) | 27.34 | <0.001** | 0.204 | 5.23 | 0.023* | 0.024 | 12.49 | <0.001** | 0.055 |
| C | 2.33 (0.89) | 2.44 (0.91) | 2.44 (0.89) | 5.74 | 0.006* | 0.051 | |||||||
Notes: a(all medication), b(antiplatelet), c(antihypertensive), *The mean difference is significant at p<0.05, **Adjustment for multiple comparisons: Bonferroni p<0.001.
Abbreviations: BIPQ, Brief Illness and Perception Questionnaire; BMQ, Belief About Medicine Questionnaire; BP, blood pressure; BP/Mon-BP monitoring; CI, confidence interval; C, control group; I, intervention group; MUSE, medication understanding and use self-efficacy; SKT, stroke knowledge test; Sys/BP-systolic BP; T0, baseline; T2, 6th month; T4, 12th month.
Pair Wise Comparison Between Timelines (T0, T2, T4)
| T0 vs T2 | T0 vs T4 | T2 vs T4 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| ∆ T2-T1(SE) | CI | p | ∆ T4-T0(SE) | CI | p | ∆ T4-T2(SE) | CI | p | ||
| MUSEa | Intervention | –4.29* (0.36) | -5.17- -3.42 | <0.001 | –4.83* (0.47) | -5.97- -3.69 | <0.001 | –0.54 (0.29) | -1.25- 0.18 | 0.211 |
| Control | –0.91* (0.32) | -1.67- -0.13 | 0.017 | –0.70 (0.33) | -1.51- 0.10 | 0.110 | 0.20 (0.17) | -0.22- 0.62 | 0.720 | |
| MUSEb | Intervention | –2.82* (0.46) | -3.94- -1.71 | <0.001 | –3.39* (0.46) | -4.51- -2.27 | <0.001 | –0.57* (0.22) | -1.11- -0.02 | 0.038 |
| Control | –1.54* (0.39) | -2.49- -0.59 | <0.001 | –1.53* (0.38) | -2.47- -0.58 | <0.001 | 0.01 (0.13) | -0.29- 0.32 | 1.00 | |
| MUSEc | Intervention | –3.27* (0.39) | -4.21- -2.33 | <0.001 | –2.57* (0.43) | -3.62- -1.53 | <0.001 | 0.69* (0.16) | 0.29- 1.09 | <0.001 |
| Control | –1.10* (0.34) | -1.93- -0.27 | 0.005 | –0.95* (0.35) | -1.82- -0.09 | 0.025 | 0.15 (0.14) | -0.19- 0.49 | 0.887 | |
| Systolic | Intervention | 7.42* (1.06) | 4.85- 9.99 | <0.001 | 5.96* (1.11) | 3.27- 8.65 | <0.001 | –1.45* (0.51) | -2.69- -0.22 | 0.015 |
| Control | 2.31 (1.08) | -0.31- 4.92 | 0.103 | 1.79 (1.09) | -0.86- 4.43 | 0.310 | –0.52 (0.52) | -1.78- 0.74 | 0.954 | |
| SKT | Intervention | –1.87* (0.16) | -2.26- -1.48 | <0.001 | –2.32* (0.18) | -2.75- -1.88 | <0.001 | –0.44* (0.09) | -0.66-0.234 | <0.001 |
| Control | –0.66* (0.11) | -0.92- -0.39 | <0.001 | –0.98* (0.13) | -1.31- -0.66 | <0.001 | –0.32* (0.08) | -0.51- -0.14 | <0.001 | |
| BIPQ | Intervention | 4.64* (0.52) | 3.36- 5.91 | <0.001 | 4.28* (0.57) | 2.90- 5.67 | <0.001 | –0.35 (0.38) | -1.28- 0.58 | 1.000 |
| Control | –0.32 (0.43) | -1.38- 0.73 | 1.000 | –0.39 (0.57) | -1.77- 0.99 | 1.000 | –0.07 (0.33) | -0.87- 0.74 | 1.000 | |
| BMQ | Intervention | 3.24* (0.41) | 2.23- 4.25 | <0.001 | 3.89* (0.51) | 2.66- 5.12 | <0.001 | –0.98* (0.31) | -1.74--0.22 | <0.001 |
| Control | –1.85* (0.42) | -2.86- -0.84 | <0.001 | –2.83* (0.50) | -4.05- -1.61 | <0.001 | 0.65 (0.28) | 0.04- 1.34 | 0.072 | |
| BP monitoring | Intervention | –0.35* (0.07) | -0.51- -0.19 | <0.001 | –0.46* (0.08) | -0.66- -0.27 | <0.001 | –0.11 (0.05) | -0.23- 0.01 | 0.068 |
| Control | –0.10* (0.04) | -0.19- -0.01 | 0.021 | –0.10* (0.04) | -0.19- -0.01 | <0.001 | 0.00 (0.03) | -0.06- 0.06 | 1.000 | |
Notes: a(all medication), b(antiplatelet), c(antihypertensive), *The mean difference (∆) is significant at p<0.05, Adjustment for multiple comparisons: Bonferroni p<0.001, CI 95% .
Figure 2Changes in mean score, measurement and frequency of outcome measures within timeline for control and intervention groups. (A) Changes in mean score of the medication understanding and use self-efficacy (MUSE) “all medications” within timeline. (B) Changes in mean score of the medication understanding and use self-efficacy (MUSE) “antiplatelet” within timeline. (C) Changes in mean score of the medication understanding and use self-efficacy (MUSE) “antihypertensive” within timeline. (D) Changes in the blood pressure (BP) measurement within timeline. (E) Changes in mean score of the brief illness and perception questionnaire (BIPQ) within timeline. (F) Changes in mean score of the stroke knowledge test (SKT) within timeline. (G) Changes in mean score of the belief about medicine questionnaire (BMQ) within timeline. (H) Changes in the blood pressure (BP) monitoring frequency within timeline.